Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Inclusion Criteria: * Adults, 18 years and older * Histologically confirmed and measurable giant cell tumor (GCT) * Recurrent GCT confirmed by radiology or unresectable GCT * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 Exclusion Criteria: * Pateints for whom surgery to the affected limb/area is planned within 27 days after receiving 1st dose of denosumab * Radiation to affected region within 28 days before enrollment to study * Known diagnosis of osteosarcoma or brown tumor of bone * Known history of second malignancy within the past 5 years, except for basal cell carcinoma or cervical carcinoma in situ * Concurrent treatment with bisphosphonates, calcitonin, or interferon. Other criteria also apply.